Kiniksa’s actions leave it focused on a cardiovascular disease pipeline led by the IL-1 antagonist KPL-387. The program is ...

Beijing appears to be extending an olive branch to the previously under-fire drug maker as it tries to shore up private ...

Shares of AstraZeneca PLC (LON:AZN – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from ...

Learn more about whether AstraZeneca PLC or Intra-Cellular Therapies, Inc. is a better investment based on AAII's A+ Investor ...

AstraZeneca will buy longtime partner FibroGen's China unit for about $160 million to gain rights to its anemia drug in the ...

AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to ...

Astrazeneca is too big and complex to base its CEO's pay on the rest of the FTSE index, according to the chair of its ...

Judging from its top line, AstraZeneca had a stellar 2024, generating an 18% increase in revenue, with 14 of the products in ...

AstraZeneca is expecting Phase III trial data for seven new medicines in 2025, its CEO said as he confirmed the company’s ...

The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foothold in China while the company works through ...

The stable outlook reflects Moody's expectation that AstraZeneca will maintain solid organic growth in revenues and EBITDA and continue to execute successfully on its new product pipeline. The outlook ...

Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be ...